These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 25629129)

  • 41. Pharmacological Characterization of a Novel Beta 3 Adrenergic Agonist, Vibegron: Evaluation of Antimuscarinic Receptor Selectivity for Combination Therapy for Overactive Bladder.
    Di Salvo J; Nagabukuro H; Wickham LA; Abbadie C; DeMartino JA; Fitzmaurice A; Gichuru L; Kulick A; Donnelly MJ; Jochnowitz N; Hurley AL; Pereira A; Sanfiz A; Veronin G; Villa K; Woods J; Zamlynny B; Zycband E; Salituro GM; Frenkl T; Weber AE; Edmondson SD; Struthers M
    J Pharmacol Exp Ther; 2017 Feb; 360(2):346-355. PubMed ID: 27965369
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Re: The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Griebling TL
    J Urol; 2015 Mar; 193(3):947. PubMed ID: 25765412
    [No Abstract]   [Full Text] [Related]  

  • 43. GW427353 (solabegron), a novel, selective beta3-adrenergic receptor agonist, evokes bladder relaxation and increases micturition reflex threshold in the dog.
    Hicks A; McCafferty GP; Riedel E; Aiyar N; Pullen M; Evans C; Luce TD; Coatney RW; Rivera GC; Westfall TD; Hieble JP
    J Pharmacol Exp Ther; 2007 Oct; 323(1):202-9. PubMed ID: 17626794
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Investigations into the presence of functional Beta1, Beta2 and Beta3-adrenoceptors in urothelium and detrusor of human bladder.
    Tyagi P; Thomas CA; Yoshimura N; Chancellor MB
    Int Braz J Urol; 2009; 35(1):76-83. PubMed ID: 19254402
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Beta-3 adrenergic agonists reduce pulmonary vascular resistance and improve right ventricular performance in a porcine model of chronic pulmonary hypertension.
    García-Álvarez A; Pereda D; García-Lunar I; Sanz-Rosa D; Fernández-Jiménez R; García-Prieto J; Nuño-Ayala M; Sierra F; Santiago E; Sandoval E; Campelos P; Agüero J; Pizarro G; Peinado VI; Fernández-Friera L; García-Ruiz JM; Barberá JA; Castellá M; Sabaté M; Fuster V; Ibañez B
    Basic Res Cardiol; 2016 Jul; 111(4):49. PubMed ID: 27328822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects and selectivity of beta-adrenoceptor agonists in rat myometrium and urinary bladder.
    Clouse AK; Riedel E; Hieble JP; Westfall TD
    Eur J Pharmacol; 2007 Nov; 573(1-3):184-9. PubMed ID: 17632099
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Enhancement of 18F-fluorodeoxyglucose metabolism in rat brain frontal cortex using a β3 adrenoceptor agonist.
    Mirbolooki MR; Schade KN; Constantinescu CC; Pan ML; Mukherjee J
    Synapse; 2015 Feb; 69(2):96-8. PubMed ID: 25347981
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony).
    Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A
    Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia.
    Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K
    Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Agonist-induced desensitisation of β
    Okeke K; Angers S; Bouvier M; Michel MC
    Br J Pharmacol; 2019 Jul; 176(14):2539-2558. PubMed ID: 30809805
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.
    Michel MC; Gravas S
    Expert Opin Drug Saf; 2016 May; 15(5):647-57. PubMed ID: 26954275
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mirabegron for overactive bladder syndrome.
    Drug Ther Bull; 2013 Aug; 51(8):90-2. PubMed ID: 23949821
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prostaglandin E2 excitatory effects on rat urinary bladder: a comparison between the β-adrenoceptor modulation of non-voiding activity in vivo and micro-contractile activity in vitro.
    Granato C; Korstanje C; Guilloteau V; Rouget C; Palea S; Gillespie JI
    Naunyn Schmiedebergs Arch Pharmacol; 2015 Jul; 388(7):727-35. PubMed ID: 26063630
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Fenoterol functionally activates the β₃-adrenoceptor in human urinary bladder, comparison with rat and mouse: implications for drug discovery.
    Palea S; Rekik M; Rouget C; Camparo P; Botto H; Rischmann P; Lluel P; Westfall TD
    Eur J Pharmacol; 2012 Sep; 690(1-3):202-6. PubMed ID: 22760074
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The new radioligand [(3)H]-L 748,337 differentially labels human and rat β3-adrenoceptors.
    van Wieringen JP; Michel-Reher MB; Hatanaka T; Ueshima K; Michel MC
    Eur J Pharmacol; 2013 Nov; 720(1-3):124-30. PubMed ID: 24183974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mirabegron for the treatment of overactive bladder.
    Gras J
    Drugs Today (Barc); 2012 Jan; 48(1):25-32. PubMed ID: 22384458
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The beta-3 adrenoceptor agonist, mirabegron relaxes isolated prostate from human and rabbit: new therapeutic indication?
    Calmasini FB; Candido TZ; Alexandre EC; D'Ancona CA; Silva D; de Oliveira MA; De Nucci G; Antunes E; Mónica FZ
    Prostate; 2015 Mar; 75(4):440-7. PubMed ID: 25417911
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of β
    Evlakhov VI; Berezina TP; Poyassov IZ
    Bull Exp Biol Med; 2020 Oct; 169(6):751-754. PubMed ID: 33119807
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacological characterization of beta-adrenoceptors mediating relaxation of the rat urinary bladder in vitro.
    Longhurst PA; Levendusky M
    Br J Pharmacol; 1999 Aug; 127(7):1744-50. PubMed ID: 10455334
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients.
    Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E
    Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.